In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Makes Its Play In Stents

Executive Summary

In building its interventional cardiology business, Abbott Laboratories has generally avoided going head-to-head with any of the major cardiovascular device players in traditional product markets such as coronary stents. But that is about to change. Its acquisition of Biocompatibles' stent business marks Abbott's entry into cardiology's major league as the company attempts to establish itself in what looks to be the next blockbuster cardiovascular device product market--drug-coated stents.
Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV001846

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel